Literature DB >> 6285153

Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy.

A Grasso, F Baraghini, C Barbieri, E Dalla Vecchia, A M Previdi, G C Di Renzo, A Volpe.   

Abstract

Prolactin (PRL), follicle stimulating hormone (FSH), luteinizing hormone (LH), oestrone (E1), and oestradiol (E2) levels were determined in 204 women who were receiving hormone replacement therapy for their climacteric symptoms. The changes in these hormone levels and the endometrial morphology were studied in order to determine the effects of the replacement therapy. The women were divided into two groups: the first group of 120 women was treated with conjugated oestrogens administered cyclically, plus norethisterone acetate. The second group of 84 women received oral oestriol succinate, also administered cyclically but without additional progestogens. The oestrogen-progestogen therapy resulted in a disappearance of the climacteric symptoms and a significant decrease of FSH and LH levels. Oestriol therapy was less effective than the conjugated oestrogens as a replacement therapy. Oestriol therapy also resulted in a less remarkable decrease of gonadotrophin levels. There were no significant changes in prolactin levels in either group of women. The endometrial histology did not change significantly after either of the two hormone replacement therapies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6285153     DOI: 10.1016/0378-5122(82)90015-9

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  3 in total

Review 1.  Pharmacologic resistance in prolactinoma patients.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Unusually high prolactin level for medication-induced hyperprolactinemia: a case report.

Authors:  Emin M Akbas; Adem Gungor; Cigdem Ozdemir; Habib Bilen
Journal:  Eurasian J Med       Date:  2013-06

Review 3.  Drugs and prolactin.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.